← Leaderboards
Arabella Young
Utah State Higher Education System--University Of Utah
$997,916
Attributed
$997,916
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2020–24$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$997,916 · 2
By mechanism
R00$747,000 · 1
K99$250,916 · 1
Top collaborators
No co-investigators on record.
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Matthew Bettini$5,997,426
- Anna E Beaudin$5,420,737
- Gianna Elena Hammer$2,251,233
- Hamid Ghandehari$11,617,654
- Jesse Aaron Goldstein$1,301,999
Others in their field
Other Emerging Leaders on “Environmental Risk Factor”
- Chanza Baytop · Westat, Inc.$271,217,917
- Scott Hensley · University Of Pennsylvania$50,236,920
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
- Dale Sandler · Social And Scientific Systems, Inc.$41,380,317
- Kristin Aillon · Midwest Research Institute$26,314,036
- Lynn Briscoe · Leidos Biomedical Research, Inc.$23,229,499
Research focus
Environmental Risk FactorEnvironmentEnvironmental ImpactAnti-Tumor Immune ResponseAutoimmunityAnti-Ctla4Autoimmune DiseasesCancer CareCancer ImmunotherapyCancer PatientCancer TherapyCancer TypeBody SystemCircadian RhythmsCombinatorialCaliforniaComplexData SetDesignDiabeticDietDimensional AnalysisEngineeringEpigenetic Process
Grant awards (5)
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity$249,000
R00 · FY2024 · CA · contact PI
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity$249,000
R00 · FY2023 · CA · contact PI
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity$249,000
R00 · FY2022 · CA · contact PI
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity$125,458
K99 · FY2021 · CA · contact PI
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity$125,458
K99 · FY2020 · CA · contact PI